Kiniksa Pharmaceuticals International (KNSA) reported a Q3 loss Tuesday of $0.18 per diluted share, narrower than a loss of $0.20 a year earlier.
Analysts surveyed by Capital IQ expected a profit of $0.10.
Revenue for the quarter ended Sept. 30 was $112.2 million, compared with $67 million a year earlier.
Analysts surveyed by Capital IQ expected $111.6 million.
The company expects 2024 Arcalyst net product revenue of between $410 million and $420 million, compared with the range of between $405 million and $415 million previously anticipated.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。